Overview

ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon

Status:
Withdrawn
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Study to evaluate efficacy of fingolimod in patients with neutralizing antibodies over 12 months
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies
Fingolimod Hydrochloride
Immunoglobulins
Interferons